The importance of IL-1α as mediator of lung inflammation has recently been shown in the randomized clinical trial SAVE-MORE; patients with pneumonia by the novel coronavirus SARS-CoV-2 were treated for 10 days with anakinra which is blocking the biological action of both IL-1α and IL-1β. This evidence concerns the gene IL1A and pneumonia.